WOONSOCKET, R.I., Aug. 10, 2012-- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce the updated preclinical research results for MCT-465 and MCT-485. MCT-485 showed in vitro dose-effect cytotoxicity on several human hepatocellular carcinoma cell lines. MCT-485 induced robust TNFalpha and some IL-6 expression. In contrast, MCT-465 showed no cytotoxicity or anti-proliferative effect. The research results support further mechanistic and in vivo studies exploring the safety, effectiveness and utility of MCT-465 and MCT-485 as novel therapeutic agents as a treatment for hepatocellular carcinoma and other cancers.
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and a leading cause of cancer death. Current pharmacological approaches for the treatment of human HCC are very limited in their efficacy. A potential role for noncoding double stranded RNAs such as MCT-465 and MCT-485 in the control of tumors has recently emerged in a variety of models with recognition of their ability to stimulate an immune response or directly affect cell death.
According to the National Cancer Institute, annually in the United States there are approximately 21,400 new cases of primary liver cancer and intrahepatic bile duct cancer, and approximately 18,400 of those cases resulted in death. Primary liver cancer, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world with more than 1 million new cases diagnosed each year. Primary liver cancer is rarely discovered early, and often does not respond to current treatment.
PR Newswire